Supplementary Materials

The PDF file includes:

  • Fig. S1. Unconjugated anti-ALK mAbs do not elicit cytotoxic activity alone or as mediators of ADCC.
  • Fig. S2. ALK is expressed in neuroblastoma but not in normal pediatric tissues.
  • Fig. S3. The DNA-alkylating CDX-0125-TEI is more potent than the CDX-0125-tubulin inhibitor.
  • Fig. S4. CDX-0125-TEI induces single-strand DNA damage.
  • Fig. S5. CDX-0125-TEI down-regulates phosphorylated ALK in treated PDXs and cell line xenografts.
  • Fig. S6. Weekly dosing with CDX-0125-TEI shows potent but transient antitumor activity in the ALK wild-type NBL-S xenograft model.
  • Table S1. List of screened ALK mAbs.
  • Table S2. Statistical analysis for in vivo efficacy studies in Felix, NBL-S, and COG-N-453x.
  • Table S3. Statistical analysis for in vivo efficacy studies in COG-N-424x and NBL-S.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: